Targeting a diverse spectrum of cancers.
Kinase switch control inhibitors for tumor-targeted and immune-targeted cancer therapies.
Deciphera’s proprietary switch control platform has generated a diverse clinical pipeline of kinase inhibitor drug candidates including tumor-targeted therapies and immuno-targeted therapies.
10/19/18 4:00 PM EDT
© Nasdaq. Minimum 15 minutes delayed.
Deciphera Pharmaceuticals Reports Updated Preliminary Phase 1 Clinical Study Results with DCC-2618 at the European Society of Medical Oncology (ESMO) 2018 Congress Read More »
Deciphera Pharmaceuticals, Inc. to Present at the 2018 Cantor Global Healthcare Conference Read More »
Deciphera Pharmaceuticals Appoints Daniel C. Martin as Chief Commercial Officer Read More »